NCT02978716 2022-03-23Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)G1 Therapeutics, Inc.Phase 2 Terminated102 enrolled 51 charts